Article and Video CATEGORIES
Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?
The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?
[powerpress]
Please feel free to offer comments and raise questions in our Discussion Forums.
Tags
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Recent Comments
Hi Hopish hope, Welcome to…
By JanineT GRACE … on
colon cancer and HIV
By Hopish hope on